Sep 13, 2023 / 08:15PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
All right. Good afternoon, everyone. I'm Tejas Savant, and I'm the life sciences analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales rep.
So it's my pleasure to host Bruker this afternoon. And on behalf of the company, we have Gerald Herman, CFO; and we also have Justin Ward, Head of Investor Relations here in the audience.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystMaybe, Gerald, just to kick things off, I just wanted to get a pulse check in terms of most of your peers being impacted by software pharma funding, headwinds in China. You actually had a pretty solid second quarter of growth in bookings in both biopharma and in China. You raised your organic growth outlook by 50 bps as well. So just set the stage, I mean
Trustpilot
